Loring Wolcott & Coolidge Fiduciary Advisors’s Alexion Pharmaceuticals Inc ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-110
| Closed | -$20K | – | 972 |
|
|
2021
Q2 | $20K | Buy |
+110
| New | +$20K | ﹤0.01% | 542 |
|
|
2021
Q1 | – | Sell |
-67
| Closed | -$10K | – | 772 |
|
|
2020
Q4 | $10K | Hold |
67
| – | – | ﹤0.01% | 574 |
|
|
2020
Q3 | $8K | Buy |
+67
| New | +$8K | ﹤0.01% | 522 |
|
|
2019
Q3 | – | Sell |
-46
| Closed | -$6K | – | 751 |
|
|
2019
Q2 | $6K | Buy |
+46
| New | +$6K | ﹤0.01% | 598 |
|
|
2018
Q1 | – | Sell |
-14
| Closed | -$2K | – | 804 |
|
|
2017
Q4 | $2K | Hold |
14
| – | – | ﹤0.01% | 673 |
|
|
2017
Q3 | $2K | Buy |
+14
| New | +$2K | ﹤0.01% | 682 |
|
|
2016
Q2 | – | Sell |
-450
| Closed | -$63K | – | 655 |
|
|
2016
Q1 | $63K | Sell |
450
-707
| -61% | -$99K | ﹤0.01% | 365 |
|
|
2015
Q4 | $221K | Buy |
1,157
+100
| +9% | +$19.1K | 0.01% | 259 |
|
|
2015
Q3 | $191K | Hold |
1,057
| – | – | ﹤0.01% | 280 |
|
|
2015
Q2 | $191K | Hold |
1,057
| – | – | ﹤0.01% | 280 |
|
|
2015
Q1 | $183K | Hold |
1,057
| – | – | ﹤0.01% | 291 |
|
|
2014
Q4 | $196K | Hold |
1,057
| – | – | 0.01% | 281 |
|
|
2014
Q3 | $175K | Hold |
1,057
| – | – | ﹤0.01% | 284 |
|
|
2014
Q2 | $165K | Sell |
1,057
-20
| -2% | -$3.12K | ﹤0.01% | 295 |
|
|
2014
Q1 | $164K | Buy |
1,077
+20
| +2% | +$3.05K | ﹤0.01% | 282 |
|
|
2013
Q4 | $140K | Buy |
1,057
+382
| +57% | +$50.6K | ﹤0.01% | 291 |
|
|
2013
Q3 | $78K | Buy |
675
+325
| +93% | +$37.6K | ﹤0.01% | 331 |
|
|
2013
Q2 | $32K | Buy |
+350
| New | +$32K | ﹤0.01% | 435 |
|